Conestoga Capital Advisors LLC Acquires 39,808 Shares of Repligen Corporation $RGEN

Conestoga Capital Advisors LLC raised its holdings in shares of Repligen Corporation (NASDAQ:RGEN) by 3.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,097,783 shares of the biotechnology company’s stock after buying an additional 39,808 shares during the quarter. Repligen comprises 2.6% of Conestoga Capital Advisors LLC’s investment portfolio, making the stock its 16th largest holding. Conestoga Capital Advisors LLC owned approximately 1.95% of Repligen worth $129,341,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. United Capital Financial Advisors LLC bought a new position in Repligen during the third quarter worth $368,387,000. Opti Capital Management LP acquired a new stake in Repligen in the 4th quarter worth $2,399,209,000. Wasatch Advisors LP acquired a new stake in Repligen in the 1st quarter worth $146,513,000. Massachusetts Financial Services Co. MA bought a new position in shares of Repligen during the 4th quarter worth about $199,176,000. Finally, Price T Rowe Associates Inc. MD increased its holdings in shares of Repligen by 31.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,599,061 shares of the biotechnology company’s stock worth $753,603,000 after purchasing an additional 1,091,683 shares during the period. 97.64% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. HC Wainwright increased their target price on shares of Repligen from $180.00 to $208.00 and gave the company a “buy” rating in a research note on Monday, March 23rd. Jefferies Financial Group restated a “hold” rating and set a $142.00 price target on shares of Repligen in a research note on Tuesday, May 5th. Rothschild & Co Redburn set a $160.00 price target on Repligen and gave the company a “buy” rating in a report on Friday, April 17th. JPMorgan Chase & Co. reduced their price objective on Repligen from $180.00 to $165.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. Finally, Weiss Ratings lowered Repligen from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, June 26th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $164.64.

Repligen Price Performance

Shares of Repligen stock opened at $138.99 on Thursday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.78 and a current ratio of 9.20. The firm’s 50-day simple moving average is $123.28 and its 200-day simple moving average is $134.85. Repligen Corporation has a twelve month low of $100.99 and a twelve month high of $175.77. The firm has a market cap of $7.84 billion, a P/E ratio of 154.44, a price-to-earnings-growth ratio of 2.63 and a beta of 1.06.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.10. The firm had revenue of $194.25 million during the quarter, compared to analyst estimates of $192.05 million. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The company’s quarterly revenue was up 14.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.39 earnings per share. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. As a group, research analysts expect that Repligen Corporation will post 1.99 EPS for the current fiscal year.

Insider Activity

In related news, CFO Jason K. Garland sold 733 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total transaction of $106,285.00. Following the completion of the transaction, the chief financial officer owned 19,359 shares in the company, valued at $2,807,055. This trade represents a 3.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.60% of the company’s stock.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.